PA8653901A1 - PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS - Google Patents

PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS

Info

Publication number
PA8653901A1
PA8653901A1 PA20058653901A PA8653901A PA8653901A1 PA 8653901 A1 PA8653901 A1 PA 8653901A1 PA 20058653901 A PA20058653901 A PA 20058653901A PA 8653901 A PA8653901 A PA 8653901A PA 8653901 A1 PA8653901 A1 PA 8653901A1
Authority
PA
Panama
Prior art keywords
indazols
piridines
pirazolo
therapeutic
formula
Prior art date
Application number
PA20058653901A
Other languages
English (en)
Inventor
Robert Michael Schelkun
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8653901A1 publication Critical patent/PA8653901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA l: EN LOS QUE R2, R3, R4, R5, R6, R7, X, Y L TIENEN CUALQUIERA DE LOS VALORES DEFINIDOS EN LA MEMORIA DESCRIPTIVA, Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, QUE SON UTILES COMO AGENTES EN EL TRATAMIENTO DE TRASTORNOS Y ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL INCLUYENDO EL TRASTORNO DE DEFICIT DE ATENCION CON HIPERACTIVIDAD, DOLOR NEUROPATICO, INCONTINENCIA URINARIA, ANSIEDAD, DEPRESION, Y ESQUIZOFRENIA Y FIBROMIALGIA. TAMBIEN SE PROPORCIONAN COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UNO O MAS COMPUESTOS DE LA FORMULA I.
PA20058653901A 2004-11-29 2005-11-29 PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS PA8653901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63138604P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
PA8653901A1 true PA8653901A1 (es) 2006-09-22

Family

ID=36218221

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058653901A PA8653901A1 (es) 2004-11-29 2005-11-29 PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS

Country Status (29)

Country Link
US (3) US7423054B2 (es)
EP (1) EP1828182B1 (es)
JP (1) JP4130219B2 (es)
KR (1) KR20070094747A (es)
CN (1) CN101111494A (es)
AP (1) AP2007004024A0 (es)
AR (1) AR051970A1 (es)
AT (1) ATE460415T1 (es)
AU (1) AU2005308523B2 (es)
BR (1) BRPI0518693A2 (es)
CA (1) CA2588812A1 (es)
CR (1) CR9155A (es)
DE (1) DE602005019913D1 (es)
DK (1) DK1828182T3 (es)
EA (1) EA012245B1 (es)
ES (1) ES2339794T3 (es)
GT (1) GT200500348A (es)
IL (1) IL183485A0 (es)
MA (1) MA29215B1 (es)
MX (1) MX2007006408A (es)
NL (2) NL1030540C2 (es)
NO (1) NO20072972L (es)
PA (1) PA8653901A1 (es)
PE (1) PE20061062A1 (es)
TN (1) TNSN07207A1 (es)
TW (1) TWI304063B (es)
UY (1) UY29228A1 (es)
WO (1) WO2006056873A2 (es)
ZA (1) ZA200704408B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
JP4130219B2 (ja) * 2004-11-29 2008-08-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 治療用のピラゾロ［３，４−ｂ］ピリジンおよびインダゾール
SG157299A1 (en) * 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
CN107082763A (zh) * 2016-02-15 2017-08-22 中山大学 一种合成吲唑酮类化合物的方法
WO2022254395A1 (en) * 2021-06-04 2022-12-08 Pi Industries Ltd. A novel process for the preparation of anthranilic diamides

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
US3712903A (en) 1968-04-17 1973-01-23 Cutter Lab 5(1-(phenyl or benzyl)-1h-indazol-3-yloxymethyl)-tetrazoles
IT1061791B (it) 1969-01-27 1983-04-30 Italfarmaco Spa Derivati indazolici ad attivita antiinfiammatoria e anagesica
US3681382A (en) 1969-02-07 1972-08-01 Ciba Geigy Corp 3-aminoindazoles
US3678059A (en) 1969-10-07 1972-07-18 Ciba Geigy Corp 3-aminoalkylidene-indazoles
IT1044784B (it) * 1970-12-15 1980-04-21 Italfarmaco Spa Farmaco adnattivita analgesica e antiinfiammatoria
DE3166987D1 (en) 1980-09-18 1984-12-06 Asahi Chemical Ind 3-aminoindazole derivatives and process for preparation thereof
JPS58159469A (ja) 1982-03-17 1983-09-21 Asahi Chem Ind Co Ltd 新規な１，３位ジ置換３−アミノインダゾ−ル誘導体およびその製造法
US4806649A (en) 1983-08-22 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3- (pyrrolidinyl)-1H-indazoles
US4775761A (en) 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4710573A (en) 1983-08-22 1987-12-01 Hoechst Roussel Pharmaceuticals, Inc. 3-(piperidinyl)-and 3-(pyrrolidinyl)-1H-indazoles
US4933460A (en) 1983-08-22 1990-06-12 Hoechst-Roussel Pharmaceuticals Inc. Piperdine substituted phenyl hydrazones
US4853470A (en) 1983-08-22 1989-08-01 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4758668A (en) 1983-08-22 1988-07-19 Hoechst-Roussel Pharmaceuticals Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
HU198036B (en) 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3338903A1 (de) 1983-10-27 1985-05-09 Basf Ag, 6700 Ludwigshafen Neue 2-phenylindazole und deren verwendung
US4999356A (en) 1987-08-07 1991-03-12 Hoechst-Roussel Pharmaceuticals, Inc. 1-phenyl-3-(1-piperazinyl)-1H-indazoles
US5134236A (en) 1987-08-07 1992-07-28 Hoechst-Roussel Pharmaceuticals Incorporated Phenylhydrazones as intermediates 1-phenyl-3-(1-piperazenyl)-1H-indazoles
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4957916A (en) 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
US5077405A (en) 1989-09-11 1991-12-31 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1-Substituted-4-piperazinyl)-1H-indazoles
JPH03223265A (ja) 1990-01-26 1991-10-02 Dainippon Pharmaceut Co Ltd 環状ジアミン誘導体
US5346968A (en) * 1990-04-21 1994-09-13 Basf Aktiengesellschaft Oligosiloxanes and reinforced thermoplastic and ceramic materials obtainable therewith
FR2663291A1 (fr) * 1990-06-15 1991-12-20 Oreal Procede pour le conditionnement d'un produit dans un flacon, permettant d'assurer une meilleure conservation du produit au cours du stockage et ensemble de conditionnement correspondant.
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2092112A1 (en) 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
DE4222705C2 (de) 1992-07-10 1996-04-04 Bartenbach Christian Reflektorelement, Reflektorelementanordnung und Raumbeleuchtungsanordnung
US5494908A (en) 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
ATE232529T1 (de) 1992-11-23 2003-02-15 Aventis Pharma Inc Substituierte 3-(aminoalkylamino)-1,2- benzisoxazole und verwandte verbindungen
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
SE502602C2 (sv) * 1994-05-26 1995-11-20 Vattenfall Ab Vägguttag
AU3162695A (en) 1994-08-03 1996-03-04 Asta Medica Aktiengesellschaft Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
GB9423682D0 (en) 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
WO1997016446A1 (en) 1995-11-02 1997-05-09 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
GB9523250D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9524356D0 (en) 1995-11-29 1996-01-31 Merck Sharp & Dohme Therapeutic agents
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
NZ333696A (en) 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
JP4351298B2 (ja) 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
US6015740A (en) * 1997-02-10 2000-01-18 Advanced Micro Devices, Inc. Method of fabricating CMOS devices with ultra-shallow junctions and reduced drain area
JP2001521926A (ja) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
JPH11279156A (ja) 1998-03-31 1999-10-12 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
DE19821002A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6316440B1 (en) 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
BR0010783A (pt) 1999-05-21 2002-04-09 Biovitrum Ab Novos compostos, seu uso e preparação
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
PL365422A1 (en) 2000-03-17 2005-01-10 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
WO2001070702A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
CN1281605C (zh) 2000-12-22 2006-10-25 惠氏公司 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
WO2002079152A1 (en) 2001-03-29 2002-10-10 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US7666867B2 (en) 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20040034101A1 (en) 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP2003146973A (ja) 2001-11-08 2003-05-21 Dai Ichi Seiyaku Co Ltd うつ病、うつ状態又は不安障害の治療及び／又は予防薬
JP2003146879A (ja) 2001-11-08 2003-05-21 Dai Ichi Seiyaku Co Ltd 精神分裂病治療及び／又は予防薬
WO2003076408A2 (en) * 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2003101994A1 (en) 2002-05-29 2003-12-11 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
JP4130219B2 (ja) * 2004-11-29 2008-08-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 治療用のピラゾロ［３，４−ｂ］ピリジンおよびインダゾール

Also Published As

Publication number Publication date
BRPI0518693A2 (pt) 2008-12-02
CA2588812A1 (en) 2006-06-01
TWI304063B (en) 2008-12-11
CR9155A (es) 2007-06-29
ATE460415T1 (de) 2010-03-15
NO20072972L (no) 2007-08-23
EA012245B1 (ru) 2009-08-28
US20060116376A1 (en) 2006-06-01
UY29228A1 (es) 2006-06-30
US20060217376A1 (en) 2006-09-28
MA29215B1 (fr) 2008-02-01
AU2005308523B2 (en) 2010-01-07
WO2006056873A3 (en) 2006-12-28
EP1828182B1 (en) 2010-03-10
WO2006056873A2 (en) 2006-06-01
GT200500348A (es) 2006-06-13
JP2008528444A (ja) 2008-07-31
PE20061062A1 (es) 2006-10-26
IL183485A0 (en) 2007-10-31
AP2007004024A0 (en) 2007-06-30
AR051970A1 (es) 2007-02-21
US20080293715A1 (en) 2008-11-27
KR20070094747A (ko) 2007-09-21
US7485636B2 (en) 2009-02-03
JP4130219B2 (ja) 2008-08-06
AU2005308523A1 (en) 2006-06-01
ZA200704408B (en) 2009-08-26
CN101111494A (zh) 2008-01-23
TW200631582A (en) 2006-09-16
US7423054B2 (en) 2008-09-09
EP1828182A2 (en) 2007-09-05
DK1828182T3 (da) 2010-05-10
ES2339794T3 (es) 2010-05-25
NL1033403A1 (nl) 2007-04-20
NL1033403C2 (nl) 2010-01-05
TNSN07207A1 (fr) 2008-11-21
DE602005019913D1 (de) 2010-04-22
NL1030540C2 (nl) 2007-02-26
EA200700963A1 (ru) 2008-02-28
NL1030540A1 (nl) 2006-05-30
MX2007006408A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
PA8631601A1 (es) Nuevos compuestos
PA8653901A1 (es) PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
CR11095A (es) Compuestos amino-heterociclicos
TW200609231A (en) Mglur1 antagonists as therapeutic agents
UY28940A1 (es) Derivados de quinazolina
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
CR20120389A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
DOP2006000141A (es) Derivados de oxindol
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
UY32391A (es) Compuestos amino-heterocíclicos
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
ATE496922T1 (de) Mglur1-antagonisten als therapeutische wirkstoffe
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.
TW200740826A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"